Contenido

Síguenos en…

Síguenos en Facebook. Pulsando en este enlace estarás saliendo de hvn.es   Síguenos en Twitter. Pulsando en este enlace estarás saliendo de hvn.es

Síguenos en YouTube. Pulsando en este enlace estarás saliendo de hvn.es   Feed de noticias

Publicaciones

Publicaciones (2012/2017)

  • C. Pérez-Ramírez, M. Cañadas-Garre, MÁ. Molina, AI. Robles, MJ. Faus-Dáder, MÁ. Calleja-Hernández. Contribution of genetic factors to platinum-based chemotherapy sensitivity and prognosis of non-small cell lung cancer.. Mutation research. 2017 771: pp. 32 - 58 (doi:10.1016/j.mrrev.2016.11.003 PMID:28342452)
  • RC. Andrés, BC. Helena, PP. Juliana, AM. Viviana, GB. Margarita, CG. Marisa. Diabetes-related neurological implications and pharmacogenomics.. Current pharmaceutical design. 2017 (doi:10.2174/1381612823666170317165350 PMID:28322157)
  • R. López-Sepúlveda, MÁ. García Lirola, E. Espínola García, JM. Jurado Martínez, S. Martín Sances, S. Anaya Ordóñez, J. Cabeza Barrera. Antidiabetic medications use trends in an Andalusian region from 2001 to 2014.. Primary care diabetes. 2017 (doi:10.1016/j.pcd.2017.01.003 PMID:28126469)
  • CL. Dávila-Fajardo, J. Sánchez-Ramos, XD. Villamarín, LJ. Martínez-González, PT. Frías, SM. Huertas, FB. Gómez, JC. Borrego, AB. Pavés, MC. Guzmán, JA. Hernández, CC. Vilches, JC. Barrera. The study protocol for a non-randomized controlled clinical trial using a genotype-guided strategy in a dataset of patients who undergone percutaneous coronary intervention with stent.. Data in brief. 2017 10: pp. 518 - 524 (doi:10.1016/j.dib.2016.12.019 PMID:28066799)
  • MÁ. Calleja Hernández, A. Herrero Ambrosio, MJ. Lamas Díaz, J. Martínez Cutillas, JL. Poveda Andrés, B. Aragón. Pharmacotherapy follow-up of patients under treatment with biologic agents for chronic inflammatory systemic conditions: an agreement among hospital pharmacists for the standardized collection of a minimum set of data.. Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria. 2017 41(n01): pp. 31 - 48 (doi:10.7399/fh.2017.41.1.10463 PMID:28045651)
  • R. López-Sepúlveda, MÁ. García Lirola, E. Espínola García, S. Martín Sances, S. Anaya Ordóñez, JM. Jurado Martínez, J. Cabeza Barrera. Effects of a primary care intervention to improve the quality of zolpidem prescriptions in elderly patients.. European journal of clinical pharmacology. 2017 73(4): pp. 455 - 461. FI: 2.71 (Cuartil Q2). (doi:10.1007/s00228-016-2180-4 PMID:28028585)
  • CH. van der Wouden, A. Cambon-Thomsen, E. Cecchin, KC. Cheung, C. Lucía Dávila-Fajardo, VH. Deneer, V. Dolžan, M. Ingelman-Sundberg, S. Jönsson, MO. Karlsson, M. Kriek, C. Mitropoulou, GP. Patrinos, M. Pirmohamed, M. Samwald, E. Schaeffeler, M. Schwab, D. Steinberger, J. Stingl, G. Sunder-Plassmann, G. Toffoli, RM. Turner, MH. van Rhenen, JJ. Swen, HJ. Guchelaar. Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium.. Clinical pharmacology and therapeutics. 2017 101(3): pp. 341 - 358 (doi:10.1002/cpt.602 PMID:28027596)
  • M. Maldonado-Montoro, M. Cañadas-Garre, A. González-Utrilla, M. Ángel Calleja-Hernández. Influence of IL6R gene polymorphisms in the effectiveness to treatment with tocilizumab in rheumatoid arthritis.. The pharmacogenomics journal. 2016. FI: 3.784 (Cuartil Q1). (doi:10.1038/tpj.2016.88 PMID:27958380)
  • MA. Pérez-Moreno, J. Cotrina-Luque, M. Galván-Banqueri, S. Flores-Moreno, FJ. Bautista-Paloma, MÁ. Calleja-Hernández. Effectiveness and safety of pemetrexed for non-small cell lung cancer in the Andalusian Public Health System.. Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria. 2016 40(n06): pp. 477 - 485 (doi:10.7399/fh.2016.40.6.10424 PMID:27894221)
  • EA. Domingues, M. Ferrit-Martín, MÁ. Calleja-Hernández. Impact of pharmaceutical care on cardiovascular risk among older HIV patients on antiretroviral therapy.. International journal of clinical pharmacy. 2016. FI: 1.339 (Cuartil Q4). (doi:10.1007/s11096-016-0387-1 PMID:27864732)
  • C. Pérez-Ramírez, M. Cañadas-Garre, AI. Robles, MÁ. Molina, MJ. Faus-Dáder, MÁ. Calleja-Hernández. Liquid biopsy in early stage lung cancer.. Translational lung cancer research. 2016 5(5): pp. 517 - 524 (doi:10.21037/tlcr.2016.10.15 PMID:27826533)
  • J. Sánchez-Ramos, CL. Dávila-Fajardo, P. Toledo Frías, X. Díaz Villamarín, LJ. Martínez-González, S. Martínez Huertas, F. Burillo Gómez, J. Caballero Borrego, A. Bautista Pavés, MC. Marín Guzmán, JA. Ramirez Hernández, C. Correa Vilches, J. Cabeza Barrera. Results of genotype-guided antiplatelet therapy in patients who undergone percutaneous coronary intervention with stent.. International journal of cardiology. 2016 225: pp. 289 - 295. FI: 4.638 (Cuartil Q1). (doi:10.1016/j.ijcard.2016.09.088 PMID:27744205)
  • J. Pasquau, S. Sadyrbaeva, SE. De Jesús, C. Hidalgo-Tenorio. [The role of antimicrobial stewardship programs in the control of bacterial resistance].. Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia. 2016 29 Suppl 1: pp. 47 - 51. FI: 1.014 (Cuartil Q4). ( PMID:27608314)
  • TM. Linares Pineda, M. Cañadas-Garre, MÁ. Calleja-Hernández. GENE POLYMORPHISMS AS PREDICTORS OF RESPONSE TO BIOLOGICAL THERAPIES IN PSORIASIS PATIENTS.. Pharmacological research. 2016 113(Pt A): pp. 71 - 80. FI: 4.816 (Cuartil Q1). (doi:10.1016/j.phrs.2016.07.020 PMID:27524442)
  • MÁ. Allende-Bandrés, F. Ruiz-Laiglesia, F. Gutiérrez-Nicolás, MÁ. Calleja Hernández. Patient safety: The pharmacist's contribution to a multidisciplinary Internal Medicine patient-care team.. Revista clinica espanola. 2016 216(9): pp. 510 - 512. FI: 0.76 (Cuartil Q3). (doi:10.1016/j.rce.2016.07.001 PMID:27499226)
  • C. Pérez-Ramírez, M. Cañadas-Garre, A. Alnatsha, E. Villar, JR. Delgado, MJ. Faus-Dáder, MÁ. Calleja-Hernández. PHARMACOGENETIC PREDICTORS OF TOXICITY TO PLATINUM BASED CHEMOTHERAPY IN NON-SMALL CELL LUNG CANCER PATIENTS.. Pharmacological research. 2016 111: pp. 877 - 884. FI: 4.816 (Cuartil Q1). (doi:10.1016/j.phrs.2016.08.002 PMID:27498158)
  • X. Díaz-Villamarín, CL. Dávila-Fajardo, LJ. Martínez-González, P. Carmona-Sáez, J. Sánchez-Ramos, MJ. Álvarez Cubero, LM. Salmerón-Febres, J. Cabeza Barrera, F. Fernández-Quesada. Genetic polymorphisms influence on the response to clopidogrel in peripheral artery disease patients following percutaneous transluminal angioplasty.. Pharmacogenomics. 2016 17(12): pp. 1327 - 1338. FI: 2.71 (Cuartil Q2). (doi:10.2217/pgs-2016-0056 PMID:27464309)
  • M. Maldonado-Montoro, M. Cañadas-Garre, A. González-Utrilla, JC. Plaza-Plaza, MÁ. Calleja-Hernández. Genetic and clinical biomarkers of tocilizumab response in patients with rheumatoid arthritis.. Pharmacological research. 2016 111: pp. 264 - 271. FI: 4.816 (Cuartil Q1). (doi:10.1016/j.phrs.2016.06.016 PMID:27339827)
  • S. Arenas-López, IM. Stanley, P. Tunstell, V. Aguado-Lorenzo, J. Philip, J. Perkins, A. Durward, MA. Calleja-Hernández, SM. Tibby. Safe implementation of standard concentration infusions in paediatric intensive care.. The Journal of pharmacy and pharmacology. 2016. FI: 2.363 (Cuartil Q2). (doi:10.1111/jphp.12580 PMID:27334458)
  • M. Cañadas-Garre, P. Becerra-Massare, A. Moreno Casares, MÁ. Calleja-Hernández, JM. Llamas-Elvira. Relevance of BRAF and NRAS mutations in the primary tumor and metastases of papillary thyroid carcinomas.. Head & neck. 2016 38(12): pp. 1772 - 1779. FI: 2.76 (Cuartil Q1). (doi:10.1002/hed.24517 PMID:27299298)
  • I. Suárez, A. Salmerón-García, J. Cabeza, LF. Capitán-Vallvey, N. Navas. Development and use of specific ELISA methods for quantifying the biological activity of bevacizumab, cetuximab and trastuzumab in stability studies.. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2016 1032: pp. 155 - 164. FI: 2.687 (Cuartil Q2). (doi:10.1016/j.jchromb.2016.05.045 PMID:27296731)
  • A. Madrid-Paredes, M. Cañadas-Garre, A. Sánchez-Pozo, AM. Segura-Pérez, CC. Santos, EV. Alcaide, LC. Portellano, MÁ. Calleja-Hernández. ABCB1 C3435T GENE POLYMORPHISM AS A POTENTIAL BIOMARKER OF CLINICAL OUTCOMES IN HER2-POSITIVE BREAST CANCER PATIENTS.. Pharmacological research. 2016 108: pp. 111 - 118. FI: 4.816 (Cuartil Q1). (doi:10.1016/j.phrs.2016.04.016 PMID:27137881)
  • MA. Moles, JA. Montoya, MD. Salvago, IR. Ávila, JJ. Campillo, M. Bravo. Implications of Differential Expression of β-Catenin in Oral Carcinoma.. Anticancer research. 2016 36(4): pp. 1599 - 1604. FI: 1.895 (Cuartil Q3). ( PMID:27069136)
  • HY. Tong, CL. Dávila-Fajardo, AM. Borobia, LJ. Martínez-González, R. Lubomirov, LM. Perea León, MJ. Blanco Bañares, X. Díaz-Villamarín, C. Fernández-Capitán, J. Cabeza Barrera, AJ. Carcas. A New Pharmacogenetic Algorithm to Predict the Most Appropriate Dosage of Acenocoumarol for Stable Anticoagulation in a Mixed Spanish Population.. PloS one. 2016 11(3): pp. e0150456 - e0150456. FI: 3.057 (Cuartil Q1). (doi:10.1371/journal.pone.0150456 PMID:26977927)
  • J. Hernández-Jiménez, A. Salmerón-García, J. Cabeza, C. Vélez, LF. Capitán-Vallvey, N. Navas. The Effects of Light-Accelerated Degradation on the Aggregation of Marketed Therapeutic Monoclonal Antibodies Evaluated by Size-Exclusion Chromatography With Diode Array Detection.. Journal of pharmaceutical sciences. 2016 105(4): pp. 1405 - 1418. FI: 2.641 (Cuartil Q2). (doi:10.1016/j.xphs.2016.01.012 PMID:26952878)
  • AJ. Pardo Cabello, E. Del Pozo Gavilán, FJ. Gómez Jiménez, C. Mota Rodríguez, JD. Luna Del Castillo, E. Puche Cañas. Drug-related mortality among inpatients: a retrospective observational study.. European journal of clinical pharmacology. 2016 72(6): pp. 731 - 736. FI: 2.71 (Cuartil Q2). (doi:10.1007/s00228-016-2026-0 PMID:26896941)
  • F. Mesa, E. Pozo, F. O'Valle, A. Puertas, A. Magan-Fernandez, E. Rosel, M. Bravo. Relationship between periodontal parameters and plasma cytokine profiles in pregnant woman with preterm birth or low birth weight.. Clinical oral investigations. 2016 20(4): pp. 669 - 674. FI: 2.207 (Cuartil Q1). (doi:10.1007/s00784-015-1553-x PMID:26245274)
  • L. González-García, A. Salmerón-García, MA. García-Lirola, S. Moya-Roldán, S. Belda-Rustarazo, J. Cabeza-Barrera. Medication reconciliation at admission to surgical departments.. Journal of evaluation in clinical practice. 2016 22(1): pp. 20 - 25. FI: 1.053 (Cuartil Q3). (doi:10.1111/jep.12403 PMID:26083630)
  • C. Pérez-Ramírez, M. Cañadas-Garre, MÁ. Molina, MJ. Faus-Dáder, MÁ. Calleja-Hernández. PTEN and PI3K/AKT in non-small-cell lung cancer.. Pharmacogenomics. 2015 16(16): pp. 1843 - 1862. FI: 2.71 (Cuartil Q2). (doi:10.2217/pgs.15.122 PMID:26555006)
  • P. Siquier Homar, M. Pinteño Blanco, MÁ. Calleja Hernández, F. Fernández Cortés, J. Martínez Sotelo. Development of integrated support software for clinical nutrition.. Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria. 2015 39(n05): pp. 240 - 268 (doi:10.7399/fh.2015.39.5.8807 PMID:26546938)
  • C. Pérez-Ramírez, M. Cañadas-Garre, MÁ. Molina, MJ. Faus-Dáder, MÁ. Calleja-Hernández. MET/HGF targeted drugs as potential therapeutic strategies in non-small cell lung cancer.. Pharmacological research. 2015 102: pp. 90 - 106. FI: 4.816 (Cuartil Q1 - Decil 3). (doi:10.1016/j.phrs.2015.09.016 PMID:26413995)
  • A. Madrid-Paredes, M. Cañadas-Garre, A. Sánchez-Pozo, MÁ. Calleja-Hernández. Non-HER2 signaling pathways activated in resistance to anti-HER2 therapy in breast cancer.. Breast cancer research and treatment. 2015 153(3): pp. 493 - 505. FI: 4.085 (Cuartil Q2 - Decil 7). (doi:10.1007/s10549-015-3578-x PMID:26400847)
  • J. Córdoba, NM. Coronado-Álvarez, D. Parra, J. Parra-Ruiz. In Vitro Activity of Novel Antimicrobial Combinations against Extensively drug-resistant Acinetobacter baumannii.. Antimicrobial agents and chemotherapy. 2015 59(12): pp. 7316 - 7319. FI: 4.415 (Cuartil Q1). (doi:10.1128/AAC.00493-15 PMID:26369956)
  • R. Ríos-Tamayo, MJ. Sánchez, JM. Puerta, J. Sáinz, DY. Chang, T. Rodríguez, P. López, JM. de Pablos, P. Navarro, JL. de Veas, A. Romero, P. Garrido, L. Moratalla, C. Alarcón-Payer, E. López-Fernández, PA. González, JJ. Jiménez-Moleón, MÁ. Calleja-Hernández, M. Jurado. Trends in survival of multiple myeloma: A thirty-year population-based study in a single institution.. Cancer epidemiology. 2015 39(5): pp. 693 - 699. FI: 2.644 (Cuartil Q3 - Decil 4). (doi:10.1016/j.canep.2015.08.002 PMID:26277330)
  • R. Morillo Verdugo, J. Sáez de la Fuente, MÁ. Calleja Hernandez. [MAPEX: look deeper, looking away].. Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria. 2015 39(4): pp. 189 - 191 (doi:10.7399/fh.2015.39.4.9407 PMID:26276736)
  • A. Madrid-Paredes, M. Cañadas-Garre, A. Sánchez-Pozo, MÁ. Calleja-Hernández. De novo resistance biomarkers to anti-HER2 therapies in HER2-positive breast cancer.. Pharmacogenomics. 2015 16(12): pp. 1411 - 1426. FI: 2.71 (Cuartil Q2). (doi:10.2217/pgs.15.88 PMID:26257318)
  • E. Puerta-García, M. Cañadas-Garre, MÁ. Calleja-Hernández. Molecular biomarkers in colorectal carcinoma.. Pharmacogenomics. 2015 16(10): pp. 1189 - 1222. FI: 2.71 (Cuartil Q2 - Decil 7). (doi:10.2217/PGS.15.63 PMID:26237292)
  • S. Belda-Rustarazo, J. Cantero-Hinojosa, A. Salmeron-García, L. González-García, J. Cabeza-Barrera, J. Galvez. Medication reconciliation at admission and discharge: an analysis of prevalence and associated risk factors.. International journal of clinical practice. 2015 69(11): pp. 1268 - 1274. FI: 2.226 (Cuartil Q1). (doi:10.1111/ijcp.12701 PMID:26202091)
  • P. García-Martín, C. Alarcón-Payer, E. López-Fernández, L. Moratalla, A. Romero, J. Sainz, R. Ríos, M. Jurado. Transplantation-Associated Thrombotic Microangiopathy in Patients Treated With Sirolimus and Cyclosporine as Salvage Therapy for Graft-Versus-Host Disease.. The Annals of pharmacotherapy. 2015 49(9): pp. 986 - 994. FI: 2.119 (Cuartil Q3 - Decil 14). (doi:10.1177/1060028015593369 PMID:26160968)
  • E. Jiménez-Varo, M. Cañadas-Garre, V. Garcés-Robles, MJ. Gutiérrez-Pimentel, MÁ. Calleja-Hernández. Extrapolation of acenocoumarol pharmacogenetic algorithms.. Vascular pharmacology. 2015 74: pp. 151 - 157. FI: 2.5 (Cuartil Q2). (doi:10.1016/j.vph.2015.06.010 PMID:26122664)
  • A. Lozano-Blázquez, R. Dickson, MD. Fraga-Fuentes, F. Martínez-Martínez, MÁ. Calleja-Hernández. Differences in cancer drug assessment between Spain and the United Kingdom.. European journal of cancer (Oxford, England : 1990). 2015 51(13): pp. 1843 - 1852. FI: 6.163 (Cuartil Q1 - Decil 3). (doi:10.1016/j.ejca.2015.04.022 PMID:26119375)
  • CGP. GOMEZ-PEÑA, CLDF. DAVILA-FAJARDO, LJMG. MARTINEZ-GONZALEZ, PCS. CARMONA-SAEZ, MJSP. SOTO-PINO, JSR. SANCHEZ-RAMOS, EME. MORENO-ESCOBAR, IB. BLANCAS, JJF. FERNANDEZ, DF. FERNANDEZ, CCV. CORREA-VILCHES, JCB. CABEZA-BARRERA. Influence of the HER2 Ile655Val polymorphism on trastuzumab-induced cardiotoxicity in HER2-positive breast cancer patients: a meta-analysis. Pharmacogenetics and genomics. 2015 25(8): pp. 388 - 393. FI: 2.857 (Cuartil Q2). (doi:10.1097/FPC.0000000000000149 PMID:26049584)
  • V. Torres-Degayón, JM. Torres-Murillo, MI. Baena-Parejo, MC. Muñoz-Villanueva, G. Montes-Redondo, MA. Calleja-Hernández, MJ. Faus-Dáder. Negative outcomes associated with medication in patients with chronic atrial fibrillation who present at the emergency department.. Journal of clinical pharmacy and therapeutics. 2015 40(4): pp. 452 - 460. FI: 1.833 (Cuartil Q3 - Decil 18). (doi:10.1111/jcpt.12289 PMID:26032557)
  • J. Martinez-Cutillas, C. Alerany-Pardo, J. Borrás-Blasco, A. Broto-Sumalla, A. Burgos-SanJosé, C. Climent-Bolta, V. Escudero-Vilaplana, MA. Fernández-Fuente, M. Ferrit-Martin, P. Gómez-Germá, JM. Martínez-Sesmero, J. Mayorga-Pérez, B. Menchén-Viso, J. Merino-Alonso, J. Polache-Vengud, A. Sánchez-Guerrero. The use of adalimumab, etanercept, golimumab and infliximab in rheumatic pathologies: variation between label dosage and real-world use.. Expert review of pharmacoeconomics & outcomes research. 2015 15(5): pp. 851 - 858. FI: 1.631 (Cuartil Q3 - Decil 5). (doi:10.1586/14737167.2015.1044514 PMID:25972066)
  • C. Pérez-Ramírez, M. Cañadas-Garre, E. Jiménez-Varo, MJ. Faus-Dáder, MÁ. Calleja-Hernández. MET: a new promising biomarker in non-small-cell lung carcinoma.. Pharmacogenomics. 2015 16(6): pp. 631 - 647. FI: 2.71 (Cuartil Q2). (doi:10.2217/pgs.15.11 PMID:25893986)
  • CLDF. DAVILA-FAJARDO, TVDS. VAN DER STRAATEN, RBP. BAAK-PABLO, CMC. MEDARDE-CABALLERO, JCB. CABEZA-BARRERA, TWH. HUIZINGA, HJG. GUCHELAAR, JJS. SWEN. FcGR genetic polymorphisms and the response to adalimumab in patients with rheumatoid arthritis. Pharmacogenomics. 2015 16(4): pp. 373 - 381. FI: 2.71 (Cuartil Q2). (doi:10.2217/pgs.14.178 PMID:25823785)
  • A. Marín Armero, MA. Calleja Hernandez, S. Perez-Vicente, F. Martinez-Martinez. Pharmaceutical care in smoking cessation.. Patient preference and adherence. 2015 9: pp. 209 - 215. FI: 1.718 (Cuartil Q2 - Decil 8). (doi:10.2147/PPA.S67707 PMID:25678779)
  • J. Turnes, R. Díaz, M. Hernandez-Guerra, M. Gómez, L. Castells, J. Bustamante, MD. Espinosa, J. Fernández-Castroagudín, T. Serrano, P. Rendón, R. Andrade, M. Salgado, J. Arenas, M. Vergara, M. Sala, BA. Polo, IM. Granizo, ML. Gonzálvez, A. Viudez. Therapeutic decisions in the treatment of hepatocellular carcinoma and patterns of sorafenib use. Results of the international observational GIDEON trial in Spain.. Gastroenterologia y hepatologia. 2015 38(4): pp. 263 - 273. FI: 0.8 (Cuartil Q4 - Decil 7). (doi:10.1016/j.gastrohep.2014.11.001 PMID:25583146)
  • MI. Baena Parejo, AM. Juanes Borrego, JA. Ruiz, MC. Monjó, M. García-Peláez, BC. Hernanz, MÁ. Calleja Hernández, MI. Chinchilla Fernández, MP. Riera, RG. Sánchez, LG. Sánchez, CV. López, MD. Mauleon Echeverria, PM. Serrano. Medication List Assessment in Spanish Hospital Emergency Departments.. The Journal of emergency medicine. 2015 48(4): pp. 416 - 423. FI: 1.048 (Cuartil Q3). (doi:10.1016/j.jemermed.2014.06.063 PMID:25547811)
  • C. Gastalver-Martín, C. Alarcón-Payer, M. León-Sanz. Individualized measurement of disease-related malnutrition's costs.. Clinical nutrition (Edinburgh, Scotland). 2015 34(5): pp. 951 - 955. FI: 4.487 (Cuartil Q1). (doi:10.1016/j.clnu.2014.10.005 PMID:25456609)
  • S. Cortés de Miguel, MA. Calleja-Hernández, S. Menjón-Beltrán, I. Vallejo-Rodríguez. Granulocyte colony-stimulating factors as prophylaxis against febrile neutropenia.. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2015 23(2): pp. 547 - 559. FI: 2.535 (Cuartil Q2 - Decil 1). (doi:10.1007/s00520-014-2459-x PMID:25284722)
  • AJ. Sastre-Heres, MA. Calero, D. Ruiz-Sánchez, MT. García, MA. Hernandez, FM. Martínez, J. Peña-Díaz. Study of the effectiveness of first-line treatment in renal cell carcinoma.. Molecular and clinical oncology. 2014 2(6): pp. 1167 - 1171 (doi:10.3892/mco.2014.353 PMID:25279217)
  • E. Jiménez-Varo, M. Cañadas-Garre, MJ. Gutiérrez-Pimentel, MA. Calleja-Hernández. Prediction of stable acenocoumarol dose by a pharmacogenetic algorithm.. Pharmacogenetics and genomics. 2014 24(10): pp. 501 - 513. FI: 3.608. (doi:10.1097/FPC.0000000000000082 PMID:25089947)
  • A. Lozano-Blázquez, C. Calvo-Pita, M. Carbajales-Álvarez, P. Suárez-Gil, F. Martínez-Martínez, MÁ. Calleja-Hernández. Drug assessment by a Pharmacy and Therapeutics committee: From drug selection criteria to use in clinical practice. Therapeutics and clinical risk management. 2014 10(1): pp. 527 - 535 (doi:10.2147/TCRM.S62572 PMID:25031538)
  • E. Jiménez-Varo, M. Cañadas-Garre, CI. Henriques, AM. Pinheiro, MJ. Gutiérrez-Pimentel, MÁ. Calleja-Hernández. Pharmacogenetics role in the safety of acenocoumarol therapy.. Thrombosis and haemostasis. 2014 112(3): pp. 522 - 536 (doi:10.1160/TH13-11-0941 PMID:24919870)
  • R. Ortega, A. Salmerón-García, J. Cabeza, LF. Capitán-Vallvey, N. Navas. Stability of daptomycin 5 mg/mL and heparin sodium 100 units/mL combined in lactated Ringer's injection and stored in polypropylene syringes at 4 and -20°C.. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2014 71(11): pp. 956 - 959 (doi:10.2146/ajhp130481 PMID:24831000)
  • S. Manrique-Rodríguez, AC. Sánchez-Galindo, J. López-Herce, MA. Calleja-Hernández, I. Iglesias-Peinado, A. Carrillo-Álvarez, MS. Sáez, CM. Fernández-Llamazares. Risks in the implementation and use of smart pumps in a pediatric intensive care unit: Application of the failure mode and effects analysis. International journal of technology assessment in health care. 2014 30(2): pp. 1 - 8. FI: 1.551 (Cuartil 3 - Decil 2). (doi:10.1017/S0266462314000051 PMID:24773916)
  • A. Montes, CLDF. DAVILA-FAJARDO, E. Perez-Pampin, J. Narváez, JD. Cañete, F. Navarro-Sarabia, V. Moreira, A. Fernández-Nebro, M. Del Carmen Ordóñez, AR. de la Serna, B. Magallares, Y. Vasilopoulos, T. Sarafidou, R. Caliz, MA. Ferrer, B. Joven, P. Carreira, JJ. Gómez-Reino, A. Gonzalez. Association of FCGR2A with the response to infliximab treatment of patients with rheumatoid arthritis. Pharmacogenetics and genomics. 2014 24(5): pp. 238 - 245. FI: 3.608 (Cuartil 1 - Decil 2). (doi:10.1097/FPC.0000000000000042 PMID:24667440)
  • A. Montes, E. Perez-Pampin, CLDF. DAVILA-FAJARDO, J. Narváez, JD. Cañete, F. Navarro-Sarabia, V. Moreira, A. Fernández-Nebro, M. Del Carmen Ordóñez, AR. de la Serna, B. Magallares, Y. Vasilopoulos, T. Sarafidou, R. Caliz, MA. Ferrer, B. Joven, P. Carreira, JJ. Gómez-Reino, A. Gonzalez. Association of FCGR2A with the response to infliximab treatment of patients with rheumatoid arthritis. Pharmacogenetics and genomics. 2014 24(5): pp. 238 - 245. FI: 3.608 (Cuartil 1 - Decil 2). (doi:10.1097/FPC.0000000000000042 PMID:24667440)
  • R. López-Sepúlveda, C. Fernández-López, C. García Collado, A. Jiménez Morales, C. Valencia Soto, MÁ. Calleja Hernández. [Boceprevir and telaprevir safety in routine clinical practice].. Farmacia hospitalaria : órgano oficial de expresión científica de la Sociedad Española de Farmacia Hospitalaria. 2014 38(1): pp. 44 - 49 ( PMID:24483859)
  • M. Cañadas-Garre, AM. Fernandez-Escamilla, G. Fernandez-Ballester, P. Becerra-Massare, C. García-Calvente, JL. Ramos, JM. Llamas-Elvira. Novel BRAFI599Ins Mutation Identified in a Follicular Variant of a Papillary Thyroid Carcinoma: A Molecular Modeling Approach.. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2014 20(5): pp. e75 - 79 (doi:10.4158/EP13465.CR PMID:24449679)
  • S. Manrique-Rodríguez, AC. Sánchez-Galindo, J. López-Herce, MÁ. Calleja-Hernández, F. Martínez-Martínez, I. Iglesias-Peinado, A. Carrillo-Álvarez, M. Sanjurjo-Sáez, CM. Fernández-Llamazares. Implementing smart pump technology in a pediatric intensive care unit: A cost-effective approach. International journal of medical informatics. 2014 83(2): pp. 99 - 105. FI: 2.061 (Cuartil 1 - Decil 1). (doi:10.1016/j.ijmedinf.2013.10.011 PMID:24296271)
  • CLDF. DAVILA-FAJARDO, AM. MARQUEZ, DPS. PASCUAL-SALCEDO, MJMR. MORENO-RAMOS, RGP. GARCIA-PORTALES, CMC. MAGRO-CHECA, JJAS. ALEGRE-SANCHO, AB. BALSA, JCB. CABEZA-BARRERA, ERA. RAYA-ALVAREZ, JM. MARTIN. Confirmation of -174G/C interleukin-6 gene promoter polymorphism as a genetic marker predicting antitumor necrosis factor treatment outcome. Pharmacogenetics and genomics. 2014 24(1): pp. 1 - 5. FI: 3.608. (doi:10.1097/FPC.0000000000000013 PMID:24253594)
  • L. Franco Trigo, MA. Calleja Hernández, JP. García Corpas. Treatment of febrile neutropenia: Filgrastim and pegfilgrastim. Ars Pharm.. 2014 55(1): pp. 1 - 7
  • A. Márquez, A. Ferreiro Iglesias, CL. Dávila Fajardo, A. Montes, D. Pascual Salcedo, E. Perez Pampin, MJ. Moreno Ramos, R. García Portales, F. Navarro, V. Moreira, C. Magro, R. Caliz, MA. Ferrer, JJ. Alegre Sancho, B. Joven, P. Carreira, A. Balsa, Y. Vasilopoulos, T. Sarafidou, J. Cabeza Barrera, J. Narvaez, E. Raya, JD. Cañete, A. Fernández Nebro, MDC. Ordóñez, AR. De la Serna, B. Magallares, JJ. Gomez Reino, A. González, J. Martín. Lack of validation of genetic variants associated with anti-tumor necrosis factor therapy response in rheumatoid arthritis: A genome-wide association study replication and meta-analysis. Arthritis Res. Ther.. 2014 16(2): pp. R66. FI: 4.302 (Cuartil 1 - Decil 1). (doi:10.1186/ar4504 )
  • R. López Sepúlveda, C. Fernández López, CG. Collado, AJ. Morales, CV. Soto, MÁC. Hernández. Boceprevir and telaprevir safety in routine clinical practice. Farm. Hosp.. 2014 38(1): pp. 44 - 49 (doi:10.7399/FH.2014.38.1.1142 )
  • TS. Casanueva, JMT. Burillo, FM. Martínez, JCV. Gámez, EN. Maestre, MAC. Hernández. Effects of a pharmaceutical care program for patients with multiple sclerosis on immunomodulatory treatment adherence. Ars Pharm.. 2014 55(1): pp. 37 - 44
  • S. Manrique-Rodríguez, AC. Sánchez-Galindo, J. López-Herce, MA. Calleja-Hernández, F. Martínez-Martínez, I. Iglesias-Peinado, A. Carrillo-Álvarez, MS. Sáez, CM. Fernández-Llamazares. Impact of implementing smart infusion pumps in a pediatric intensive care unit.. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2013 70(21): pp. 1897 - 1906. FI: 1.984 (Cuartil 3 - Decil 15). (doi:10.2146/ajhp120767 PMID:24128965)
  • CLDF. DAVILA-FAJARDO, JJS. SWEN, JCB. CABEZA-BARRERA, HJG. GUCHELAAR. Genetic risk factors for drug-induced liver injury in rheumatoid arthritis patients using low-dose methotrexate. Pharmacogenomics. 2013 14(1): pp. 63 - 73 (doi:10.2217/pgs.12.183 PMID:23252949)
  • MA. Calleja, JM. Vieites, T. Montero-Meterdez, MI. Torres, MJ. Faus, A. Gil, A. Suárez. The antioxidant effect of β-caryophyllene protects rat liver from carbon tetrachloride-induced fibrosis by inhibiting hepatic stellate cell activation. The British journal of nutrition. 2013 109(3): pp. 394 - 401. FI: 3.302 (Cuartil 1 - Decil 2). (doi:10.1017/S0007114512001298 PMID:22717234)
  • MS. Legnoverde, I. Jiménez Morales, A. Jiménez Morales, E. Rodríguez Castellón, EI. Basaldella. Modified silica matrices for controlled release of cephalexin. Med. Chem.. 2013 9(5): pp. 672 - 680. FI: 1.373 (Cuartil 4 - Decil 4).
  • RJ. Galán, EC. Cidoncha, MF. Martin, CC. Rodriguez, CVA. González, RM. Verdugo. Antiviral regimen complexity index as an independent predictor of sustained virologic response in patients with chronic hepatitis C. J. Managed Care Pharm.. 2013 19(6): pp. 448 - 453. FI: 2.414 (Cuartil 1 - Decil 2).
  • AM. Alañón Pardo, R. Ubago Pérez, MÁ. Calleja HernÁndez, P. Araque Arroyo, B. Candela Díez, M. Ferrit MartÍn. Adaptation of the chemotherapy prescription for breast cancer in a tertiary hospital. Impact on survival. Aten. Farm.. 2013 15(3): pp. 178 - 184. FI: 0.125 (Cuartil 4 - Decil 25).
  • B. Cancela Díez, F. Gutiérrez Nicolás, P. Araque Arroyo, AM. Alañón Pardo, M. Salazar Bravo, MÁ. Calleja Hernández. Methotrexate monitoring in serum and cerebrospinal fluid (CSF) of patient with medulloblastoma. Aten. Farm.. 2013 15(2): pp. 128 - 130. FI: 0.125.
  • M. Heredia, JM. Tenías, R. Rocio, F. Amparo, MA. Calleja, JC. Valenzuela. Quality of life and predictive factors in patients undergoing assisted reproduction techniques. European journal of obstetrics, gynecology, and reproductive biology. 2013 167(2): pp. 176 - 180. FI: 1.843 (Cuartil 2 - Decil 3). (doi:10.1016/j.ejogrb.2012.12.011 )
  • RM. Romero Jiménez, MA. Calleja Hernández, M. Chaparro Recio, F. Martínez Martínez, M. Sanjurjo Sáez. Effect of pharmacotherapy follow-up on treatment adherence and virologic and immune response in patients with human immunodeficiency virus. Lat. Am. J. Pharm.. 2013 32(3): pp. 441 - 447. FI: 0.244 (Cuartil 4 - Decil 25).
  • V. Martínez Santana, E. González Sarmiento, M. Calleja Hernández, T. Sánchez Sánchez. Comparison of drug survival rates for tumor necrosis factor antagonists in rheumatoid arthritis. Patient Preference Adherence. 2013 pp. 719 - 727. FI: 1.333 (Cuartil 2 - Decil 6). (doi:10.2147/PPA.S47453 )
  • C. García Muñoz, C. Alarcón Payer, I. Cañamares Orbis, MJ. Jiménez Cerezo, JM. Ferrari Piquero, MA. Calleja Hernández. Therapeutic interchange programs in Spain and abroad. Aten. Farm.. 2013 15(4): pp. 279 - 285. FI: 0.125 (Cuartil 4 - Decil 25).
  • MAA. Bandres, MA. Mendoza, FG. Nicolás, MAC. Hernandez, FR. La Iglesia. Pharmacist-led medication reconciliation to reduce discrepancies in transitions of care in Spain. Int. J. Clin. Pharm.. 2013 35(6): pp. 1083 - 1090. FI: 0.859 (Cuartil 4 - Decil 21). (doi:10.1007/s11096-013-9824-6 )
  • T. Sánchez Casanueva, JM. Tenías Burillo, F. Martínez Martínez, JC. Valenzuela Gámez, E. Navarro Maestre, MÁ. Calleja Hernández. Effects of a pharmaceutical care program for patients with multiple sclerosis on immunomodulatory treatment adherence. Ars Pharm.. 2013 54(4): pp. 2 - 8
  • AM. MARQUEZ, CLDF. DAVILA-FAJARDO, GR. ROBLEDO, JLCR. CALLEJAS-RUBIO, ERG. DE RAMON GARRIDO, FJGH. GARCIA-HERNANDEZ, RGL. GONZALEZ-LEON, RRF. RIOS-FERNANDEZ, JCB. CABEZA-BARRERA, MFGE. GONZALEZ-ESCRIBANO, MTCG. CAMPS-GARCIA, MJCP. CASTILLO-PALMA, MMA. AYALA, NOC. ORTEGO-CENTENO, JM. MARTIN. IL2/IL21 region polymorphism influences response to rituximab in systemic lupus erythematosus patients. Molecular Biology Reports. 2013 40(8): pp. 4851-6 (doi:10.1007/s11033-013-2583-6 )
  • C. Alarcón Payer, A. Jiménez Morales, A. Del Saz Caracuel, MÁC. Hernández. Effectiveness and safety of sodium oxybate in narcolepsy-cataplexy syndrome. Euro. J. Hosp. Pharm. Sci. Pra.. 2013 20(1): pp. 32 - 35 (doi:10.1136/ejhpharm-2012-000122 )
  • AS. Díaz, JS. De La Fuente, L. Esteva, AMA. Pardo, N. Barrueco, C. Esteban, IE. Rodríguez. Drug prescribing in patients with renal impairment optimized by a computer-based, semi-automated system. Int. J. Clin. Pharm.. 2013 35(6): pp. 1170 - 1177. FI: 0.859. (doi:10.1007/s11096-013-9843-3 )
  • M. Muros Ortega, MS. Díaz Carrasco, A. Capel, MA. Calleja, F. Martínez. Effectiveness and safety of doxorubicin loaded beads in hepatocellular carcinoma. Int. J. Clin. Pharm.. 2013 35(6): pp. 1105 - 1112. FI: 0.859 (Cuartil 4 - Decil 21). (doi:10.1007/s11096-013-9831-7 )
  • KR. Venegas, MA. Gómez, MC. Garre, AG. Sánchez, C. Contreras-Ortega, MA. Hernández. Pharmacogenetics of osteoporosis: Towards novel theranostics for personalized medicine?. Omics : a journal of integrative biology. 2012 16(12): pp. 638 - 651. FI: 2.441 (Cuartil Q2). (doi:10.1089/omi.2011.0150 PMID:23215803)
  • JC. Plaza-Plaza, M. Aguilera, M. Cañadas-Garre, C. Chemello, A. González-Utrilla, MJ. Faus Dader, MA. Calleja. Pharmacogenetic polymorphisms contributing to toxicity induced by methotrexate in the southern Spanish population with rheumatoid arthritis. Omics : a journal of integrative biology. 2012 16(11): pp. 589 - 595. FI: 2.441 (Cuartil Q2). (doi:10.1089/omi.2011.0142 PMID:23095111)
  • V. Martínez Santana, M. Izquierdo Navarro, MA. Calleja Hernández, T. Sánchez Sánchez, M. Sainz Gil. Severe pancytopenia following etanercept administration in rheumatoid arthritis. International Journal of Rheumatic Diseases . 2012 15(4): pp. e78 - e79. FI: 0.807 (Cuartil Q4). (doi:10.1111/j.1756-185X.2012.01740.x PMID:22898233)
  • M. Heredia, JM. Tenías, M. Sanchez, MD. Fraga, MA. Calleja, JC. Valenzuela. Drug tolerability in assisted reproduction techniques: A longitudinal study. Systems Biology in Reproductive Medicine . 2012 58(5): pp. 245 - 254. FI: 1.524 (Cuartil Q3). (doi:10.3109/19396368.2012.687036 PMID:22612224)
  • CM. Fernandez Llamazares, MA. Calleja Hernández, S. Manrique Rodríguez, C. Pérez Sanz, E. Durán García, M. Sanjurjo Sáez. Prescribing errors intercepted by clinical pharmacists in paediatrics and obstetrics in a tertiary hospital in Spain. European Journal of Clinical Pharmacology . 2012 68(9): pp. 1339 - 1345. FI: 2.845 (Cuartil Q2). (doi:10.1007/s00228-012-1257-y PMID:22392558)
  • CM. Fernández Llamazares, MA. Calleja Hernandez, S. Manrique Rodriguez, C. Pérez Sanz, E. Duran García, M. Sanjurjo Saez. Impact of clinical pharmacist interventions in reducing paediatric prescribing errors. Archives of Disease in Childhood . 2012 97(6): pp. 564 - 568. FI: 2.881 (Cuartil Q1). (doi:10.1136/archdischild-2011-301239 PMID:22362718)
  • P. Aznarte Padial, S. Perez Vicente, A. Zarzuelo Zurita, MA. Calleja Hernández. Monitoring of quality indicators of prescriptions after acute myocardial infarction. Revista de calidad asistencial : organo de la Sociedad Espanola de Calidad Asistencial. 2012 27(3): pp. 155 - 160 (doi:10.1016/j.cali.2011.09.009 PMID:22137198)
  • JE. Vargas Rivas, MM. Montes Casas, B. Cancela Diez, F. Martínez Martínez, D. Sabater Hernández, MA. Calleja Hernández. Study of compliance with prescription information sheet of trastuzumab prescriptions in a tertiary level hospital. Farmacia Hospitalaria . 2012 36(3): pp. 135 - 140 (doi:10.1016/j.farma.2011.02.009 PMID:22137162)
  • S. Cortijo Cascajares, I. Nacle López, I. García Escobar, MJ. Aguilella Vizcaíno, A. Herreros de Tejada, H. Cortés Funes Castro, MA. Calleja Hernández. Effectiveness of oxaliplatin desensitization protocols. Clin. Transl. Oncol.. 2012 15(3): pp. 1 - 7. FI: 1.327 (Cuartil Q4). (doi:10.1007/s12094-012-0909-9 )
  • C. Sánchez Gil, J. Antequera Rodríguez Rabadán, A. Such Díaz, L. Alonso Pérez, A. Fernández Vázquez, MA. Calleja Hernández. Role of the community pharmacist in the management of arterial hypertension. Atencion Farmaceutica . 2012 14(2): pp. 108 - 115. FI: 0.082 (Cuartil Q4).
  • C. Cano Corral, ML. González Rodríguez, JI. Pérez Martínez, C. Alarcón Payer, I. Martínez López, A. Rabasco Álvarez. Description and characterization of an oily omeprazole suspension for administration in children. Ars Pharmaceutica . 2012 53(2 ): pp. 29-35 (doi:http://gerion.greendata.es:443/sfxlcl3?sid=EMBASE&issn=00042927&id=doi:&atitle=Description+and+characterization+of+an+oily+omeprazole+suspension+for+administration+in+children&stitle=Ars+Pharm.&title=Ars+Pharmaceutica&volume=53&issue=2&spage=29&epage=35&a )
  • CM. Fernández-Llamazares, S. Manrique-Rodríguez, C. Pérez-Sanz, ME. Durán-García, M. Sanjurjo-Sáez, MA. Calleja-Hernández. Validation of a method for recording pharmaceutical interventions. Journal of Clinical Pharmacy and Therapeutics . 2012 37(4): pp. 459 - 463. FI: 2.104 (Cuartil Q3 - Decil 14). (doi:10.1111/j.1365-2710.2011.01328.x )
  • P. Araque Arroyo, P. Cuesta Santos, M. Ferrit Martín, B. Cancela Díez, AM. Alañón Pardo, JC. Valenzuela Gámez, MÁ. Calleja Hernández. Effectiveness of off-label use of bevacizumab in recurrent ovarian and metastatic breast cancer. Atencion Farmaceutica . 2012 14(3): pp. 167 - 173. FI: 0.082 (Cuartil Q4).
  • ME. Colmenares, C. Labastida, P. Aznarte Padial, MÁ. Calleja Hernández, F. Martínez Martínez. Suitability of perioperative antimicrobial prophylaxis in appendicitis. Atencion Farmaceutica . 2012 14(4): pp. 245 - 250. FI: 0.082 (Cuartil Q4).
  • GR. ROBLEDO, AM. MARQUEZ, CLDF. DAVILA-FAJARDO, NOC. ORTEGO-CENTENO, JLCR. CALLEJAS-RUBIO, ERG. DE RAMON GARRIDO, JSR. SANCHEZ-ROMAN, FJGH. GARCIA-HERNANDEZ, RRF. RIOS-FERNANDEZ, MFGE. GONZALEZ-ESCRIBANO, MTCG. CAMPS-GARCIA, MJCP. CASTILLO-PALMA, MMA. AYALA, JM. MARTIN. Association of the FCGR3A-158F/V gene polymorphism with the response to rituximab treatment in Spanish systemic autoimmune disease patients. DNA Cell Biol. 2012 31(12): pp. 1671-7 (doi:10.1089/dna.2012.1799 )
  • AMC. Cruz, JMM. Villares, PG. Munoz, MAV. Zanuy, MAC. Hernandez. PILOT STUDY OF INTRAVENOUS FLUID THERAPY MANAGEMENT IN ADULT PATIENTS AT A TERTIARY CARE HOSPITAL. NUTRICION HOSPITALARIA. 2012 27(3): pp. 943 - 947. FI: 1.12 (Cuartil Q4). (doi:10.3305/nh.2012.27.3.5744 )
  • L. González García, C. Chemello, F. García Sánchez, DC. Serpa Anaya, C. Gómez González, L. Soriano Carrascosa, MP. de Rueda, M. Moya Molina, F. Sánchez García, M. Ortega Calvo. Aphorisms and short phrases as pieces of knowledge in the pedagogical framework of the Andalusian school of public health. International Journal of Preventive Medicine . 2012 3(3): pp. 197 - 210
  • P. Araque Arroyo, F. Manzano Manzano, P. Cuesta Santos, A. Plá Hernández, JC. Valenzuela Gámez, MA. Calleja Hernández. Monitoring of serum and urinary levels of ethylene glycol after large intake concomitant with ethanol consumption. Atencion Farmaceutica . 2012 14(5): pp. 376 - 378. FI: 0.082 (Cuartil Q4).
  • E. Durán García, CM. Fernandez Llamazares, MA. Calleja Hernández. Medication reconciliation: Passing phase or real need?. International Journal of Clinical Pharmacy . 2012 34(6): pp. 797 - 802 (doi:10.1007/s11096-012-9707-2 )
  • M. Heredia, JM. Tenías, R. Ruiz, M. Sanchez, MA. Calleja, F. Martinez. Pharmaceutical care for patients undergoing assisted reproduction techniques. European Journal of Hospital Pharmacy: Science and Practice . 2012 19(3): pp. 289 - 292 (doi:10.1136/ejhpharm-2012-000099 )
  • I. Yeste Gómez, M. Ferrit Martín, E. Durán García, B. Marzal Alfaro, A. Giménez Manzorro , M. Sanjurjo Sáez. Ferric carboxymaltose: Efficacy and safety. Atencion Farmaceutica . 2012 14(4): pp. 251 - 261. FI: 0.082 (Cuartil Q4).
  • D. Ruiz Sánchez, MA. Calero, AJ. Sastre Heres, MTI. García, MAC. Hernandez, FM. Martinez, J. Peña. Effectiveness of the bevacizumab-irinotecan regimen in the treatment of recurrent glioblastoma multiforme: Comparison with other second-line treatments without this regimen. Oncology Letters . 2012 4(5): pp. 1114 - 1118. FI: 0.108 (Cuartil Q4). (doi:10.3892/ol.2012.861 )
Última actualización de datos: 19-05-2017
23.192.311 visitas desde el 1 de Marzo de 2006
Última actualización de la pagina: 22-01-2016 Subir
Certificación Emas Certificacion Responsabilidad Social Certificacion Gestión Ambiental Certificacion Seguridad Alimentaria Certificacion Salud Laboral
Las páginas del dominio hvn.es cumplen con las normas de accesibilidad WCAG 2.0 nivel AAA
hvn.es cumple con las normas de W3C para el lenguaje de marcado XHTML 1.0
hvn.es cumple con las normas de W3C para hojas de estilo
FIBAO IBS Logo de Green Light Logo de OMARS Logo de Living Lab Salud Andalucía Red de Comités de Ética del SSPA CEI Biotic - Granada
Datos de Contacto | Webmaster | Mapa web | Nota legal | Política editorial | Uso del sitio | Accesibilidad | Preguntas frecuentas | RSS
© 2003 - 2017. Hospital Universitario Virgen de las Nieves.
- HUVN -